Comparison
While PEG-MGF is used experimentally to enhance muscle repair and hypertrophy after mechanical overload or injury by stimulating satellite-cell activation and protein synthesis6373138, Semaglutide is approved for type 2 diabetes and chronic weight management, significantly lowering HbA1c and body weight by modulating incretin pathways232480.
While PEG-MGF works as a poly(ethylene glycol)-conjugated form of Mechano Growth Factor (IGF-1Ec splice variant) comprising the 24-aa C-terminal E-peptide of IGF-1, designed to extend half-life while activating IGF-1 receptor–mediated anabolic signaling in muscle satellite cells637322138, Semaglutide is a modified GLP-1(7–37) analog with three key changes—Ala8→Aib, Lys26 acylated with a C18 fatty diacid, and Lys34→Arg—resulting in a long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite23647480.
PEG-MGF is 24 amino acids long, whereas Semaglutide is longer as it has a length of 31 amino acids. PEG-MGF is made up of a sequence of Tyrosine, Glutamine, Proline, Proline, Serine, Threonine, Asparagine, Lysine, Asparagine, Threonine, Lysine, Serine, Glutamine, Arginine, Arginine, Lysine, Glycine, Serine, Threonine, Phenylalanine, Glutamic acid, Glutamic acid, Arginine, Lysine. Semaglutide is made up of a sequence of sequence data not available in the current dataset.
PEG-MGF
IGF1
Semaglutide
GCG